Header cover image

Investing Ideas
/
Swiss Pharmaceuticals & Biotech Top Stock Picks from Analysts

Swiss Pharmaceuticals & Biotech Top Stock Picks from Analysts

Results

7

0 new

Companies which are more than 50% undervalued based on analyst price target.

7 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
	COPN Cosmo Pharmaceuticals	CHF 62.90	1.6%	46.3%	CHF 1.0b	CHF 97.30	PE15.6x	E17.2%	3.0%
	BSLN Basilea Pharmaceutica	CHF 41.40	2.1%	19.3%	CHF 495.1m	CHF 77.25	PS3.4x	E20.1%	0%
	MOLN Molecular Partners	CHF 5.24	8.8%	34.4%	CHF 192.1m	CHF 9.75	PS32.2x	E-1.2%	n/a
	IDIA Idorsia	CHF 0.84	11.7%	-56.0%	CHF 151.0m	CHF 1.60	PS2.1x	E15.1%	n/a
	NWRN Newron Pharmaceuticals	CHF 7.60	4.4%	63.4%	CHF 145.9m	CHF 14.42	PS22.8x	E56.5%	n/a
	SANN Santhera Pharmaceuticals Holding	CHF 8.27	4.7%	-7.1%	CHF 98.7m	CHF 32.00	PE1.6x	E35.4%	n/a
	ADXN Addex Therapeutics	CHF 0.062	9.9%	44.9%	CHF 6.2m	CHF 0.16	PS10.3x	E21.7%	n/a

Page 1 of 1